Viewing Opinion | StockChase

Johnson & Johnson (JNJ-N) opinion on 2017-10-11

Last Price Recorded: 142.4600 on 2017-12-15

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical
biotechnology/pharmaceutical
TOP PICK

Christine Poole
Johnson & Johnson was $136.650 at time of opinion
Owned : Yes

The US$ has weakened against all currencies this year, and for US multinationals that is going to be a nice tailwind for them. About 50% of revenues come from North America. About 45% of revenues come from the pharmaceutical division, and then they have the medical devices and the consumer products division. Their Pharma division has really started to show nice organic growth, and investments in their pipeline are paying off. Going forward, management has indicated they expect to file 10 new products by 2019 with revenue potential of $1 billion, so she sees good visibility in the pipeline going forward. Organic growth is picking up. They increase the dividend every year and have done so for the last 55 years. Dividend yield of 2.5%. (Analysts’ price target is $142.)

OPTIMISTIC

All opinions for JNJ-N (382)

116 BUY
17 BUY on WEAKNESS
50 COMMENT
44 DON'T BUY
28 HOLD
3 PARTIAL BUY
5 PARTIAL SELL
36 PAST TOP PICK
3 SELL
1 STRONG BUY
61 TOP PICK
3 VAGUE
6 WAIT
5 WATCH
4 WEAK BUY
View All

More experts covering JNJ-N

SAVE
Add JNJ-N to Watch List

All opinions for JNJ-N (382)

116 BUY
17 BUY on WEAKNESS
50 COMMENT
44 DON'T BUY
28 HOLD
3 PARTIAL BUY
5 PARTIAL SELL
36 PAST TOP PICK
3 SELL
1 STRONG BUY
61 TOP PICK
3 VAGUE
6 WAIT
5 WATCH
4 WEAK BUY
View All

More experts covering JNJ-N

SAVE
Add JNJ-N to Watch List

Last 60 Days Opinions

HOLD
2 days ago
PAST TOP PICK
4 days ago
COMMENT
1 month ago

No Comments.


You must be logged in to comment.

Successfully Saved Company